EUVIMEDSkopri EUVIMED
Open access

The severity of SARS‐CoV‐2 infection in K18‐hACE2 mice is attenuated by a novel steroid‐derivative in a gender‐specific manner

Sachin A Gupte iD, Chandra Shekhar Bakshi, Emma Blackham, Gerald E Duhamel, Allan Jordan, Padmini Salgame, Melinee D'silva, Mohammad Y Khan, Jerry Nadler, Rakhee Gupte

British Journal of Pharmacology · 2023-10 · 180 (20) · 2677-2693

DOI: 10.1111/bph.16155 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2023-07-05. Written by Sachin A Gupte and 9 co-authors. Institution: Department of Pharmacology, New York Medical College, Valhalla, New York, USA. Major MEDLINE topics: COVID-19. Cited 12 times so far (Crossref); 40 references. The full text is freely available in PubMed Central. Funded by: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background and Purpose COVID‐19 infections caused by SARS‐CoV‐2 disseminated through human‐to‐human transmission can evoke severe inflammation. Treatments to reduce the SARS‐CoV‐2‐associated inflammation are needed and are the focus of much research. In this study, we investigated the effect of N ‐ethyl‐ N ′‐[(3β,5α)‐17‐oxoandrostan‐3‐yl] urea (NEOU), a novel 17α‐ketosteroid derivative, on the severity of COVID‐19 infections. Experimental Approach Studies were conducted in SARS‐CoV‐2‐infected K18‐hACE2 mice. Key Results SARS‐CoV‐2‐infected K18‐hACE2 mice developed severe inflammatory crises and immune responses along with up‐regulation of genes in associated signalling pathways in male more than female mice. Notably, SARS‐CoV‐2 infection down‐regulated genes encoding drug metabolizing cytochrome P450 enzymes in male but not female mice. Treatment with NEOU (1 mg·kg −1 ·day −1 ) 24 or 72 h post‐viral infection alleviated lung injury by decreasing expression of genes encoding inflammatory cytokines and chemokines while increasing expression of genes encoding immunoglobins. In situ hybridization using RNA scope™ probes and immunohistochemical assays revealed that NEOU increased resident CD169 + immunoregulatory macrophages and IBA‐1 immunoreactive macrophage‐dendritic cells within alveolar spaces in the lungs of infected mice. Consequentially, NEOU reduced morbidity more prominently in male than female mice. However, NEOU increased median survival time and accelerated recovery from infection by 6 days in both males and females. Conclusions and Implications These findings demonstrate that SARS‐CoV‐2 exhibits gender bias by differentially regulating genes encoding inflammatory cytokines, immunogenic factors and drug‐metabolizing enzymes, in male versus female mice. Most importantly, we identified a novel 17α‐ketosteroid that reduces the severity of COVID‐19 infection and could be beneficial for reducing impact of COVID‐19.

Subjects

MeSH terms (MEDLINE)

COVID-19HumansFemaleMaleAnimalsMiceSARS-CoV-2SexismSteroidsKetosteroidsCytokinesInflammationMice, TransgenicDisease Models, AnimalLunggamma-GlobulinsMelphalan

Author keywords

CD169+ macrophagesCOVID-19IBA-1 immunoreactive macrophage-dendritic cellsRNA scopelung damagemortalitysurvivalweight loss

Substances

SteroidsKetosteroidsCytokinesK-18 conjugategamma-GlobulinsMelphalan

Authors and institutions

  • Department of Pharmacology, New York Medical College, Valhalla, New York, USA.
  • Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, New York, USA.
  • Sygnature Discovery Limited, Nottingham, UK.
  • Department of Biomedical Sciences and New York State Animal Health Diagnostic Center and Section of Anatomic Pathology, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
  • Department of Medicine, Division of Infectious Diseases and The Center for Emerging Pathogens, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.
  • Department of Medicine, New York Medical College, Valhalla, New York, USA.

ORCID profiles: Sachin A Gupte

Funding

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Cite

APA

Gupte, S. A., Bakshi, C. S., Blackham, E., Duhamel, G. E., Jordan, A., Salgame, P., D'silva, M., Khan, M. Y., Nadler, J., & Gupte, R. (2023). The severity of SARS‐CoV‐2 infection in K18‐hACE2 mice is attenuated by a novel steroid‐derivative in a gender‐specific manner. British Journal of Pharmacology, 180(20), 2677-2693. https://doi.org/10.1111/bph.16155

Vancouver

Gupte SA, Bakshi CS, Blackham E, Duhamel GE, Jordan A, Salgame P, et al. The severity of SARS‐CoV‐2 infection in K18‐hACE2 mice is attenuated by a novel steroid‐derivative in a gender‐specific manner. British Journal of Pharmacology. 2023;180(20):2677-2693. doi:10.1111/bph.16155

BibTeX
@article{Gupte2023,
  author = {Gupte, Sachin A and Bakshi, Chandra Shekhar and Blackham, Emma and Duhamel, Gerald E and Jordan, Allan and Salgame, Padmini and D'silva, Melinee and Khan, Mohammad Y and Nadler, Jerry and Gupte, Rakhee},
  title = {The severity of SARS‐CoV‐2 infection in K18‐hACE2 mice is attenuated by a novel steroid‐derivative in a gender‐specific manner},
  journal = {British Journal of Pharmacology},
  year = {2023},
  volume = {180},
  number = {20},
  pages = {2677--2693},
  doi = {10.1111/bph.16155}
}
Start for free →